Affinity Asset Advisors portfolio
Investment firmPortfolio as of Jun 30, 2026 (Q2 2026) · filed with the SEC on Aug 13, 2026 · data updated on Nov 5, 2026 · Q2 2026 13F (filing) ↗ · all its 13F filings ↗
A 13F shows the portfolio at quarter-end and is filed up to 45 days later: these are not real-time positions and they may have changed.
Affinity Asset Advisors reported a $2.0 bn portfolio of 100 companies (101 positions, counting each share class separately) to the SEC as of the end of Q2 2026. Its largest positions are ROIV, Apogee Therapeutics, SYRE. During the quarter it opened IDEAYA Biosciences.
Sections with a free account
What it reported after the quarter end (Q2 2026)
The 13F shows the portfolio as of Jun 30, 2026. Since then Affinity Asset Advisors has filed these own trades with the SEC (Form 4, when it owns more than 10% of a company or holds a role in it) and stakes above 5% (13D and 13G). It is not everything it did: only what it must report before the next 13F.
Stake reported in the company · event of Jun 30, 2026 · filed Aug 13, 2026 · filing ↗
Stake reported in the company · event of Jun 30, 2026 · filed Aug 13, 2026 · filing ↗
Stake reported in the company · event of Jun 30, 2026 · filed Aug 13, 2026 · filing ↗
Stake reported in the company · event of Jun 30, 2026 · filed Aug 13, 2026 · filing ↗
Stake reported in the company · event of Jun 30, 2026 · filed Aug 13, 2026 · filing ↗
Stake reported in the company · event of Jun 30, 2026 · filed Aug 13, 2026 · filing ↗
Stake reported in the company · event of Jun 30, 2026 · filed Aug 13, 2026 · filing ↗
Stake reported in the company · event of Jun 30, 2026 · filed Aug 13, 2026 · filing ↗
Plus 1 more, in its EDGAR filings.
What changed this quarter
75 positions with a change (10 new, 32 added to, 30 trimmed, 3 sold); also, 2 entered through an IPO, 4 exited through an acquisition or merger, 4 entered through a spin-off. 12 are listed here: those of 0.5 points of the portfolio or more (up to 12).
- Apogee Therapeutics−23%fewer sharesReduced6.5% → 6.5%
- Teva Pharmaceutical Industries−73%fewer sharesReduced2.5% → 0.6%
- Roivant Sciences+34%more sharesIncreased4.6% → 6.6%
- Avalo Therapeutics+116%more sharesIncreased1.2% → 2.7%
- Revolution Medicines+150%more sharesIncreased0.6% → 2.3%
- Insmed+35%more sharesIncreased4.7% → 3.4%
- Ascendis Pharma A/S−68%fewer sharesReduced1.3% → 0.4%
- Belite Bio+154%more sharesIncreased0.6% → 1.3%
- IDEAYA Biosciences+0.7 ppof portfolioNew— → 0.7%
- Cytokinetics−21%fewer sharesReduced2.8% → 2.3%
- Sagimet Biosciences+188%more sharesIncreased0.3% → 1.0%
- Relay Therapeutics+163%more sharesIncreased0.2% → 1.0%
The figure on the right: for positions added to or trimmed, the change in the number of shares (%); for new and sold ones, the points of the portfolio moved (pp). Below, the portfolio weight before → after. Traded weight: what it bought or sold, excluding price effects.
Top holdings
- Roivant SciencesROIV6.6%
- Apogee Therapeutics6.5%
- Spyre TherapeuticsSYRE5.6%
- Xenon PharmaceuticalsXENE4.8%
- ErascaERAS4.8%
- InsmedINSM3.4%
- Praxis Precision MedicinesPRAX3.1%
- Alkermes plc.ALKS2.9%
- Oruka TherapeuticsORKA2.8%
- AnaptysbioANAB2.8%
- Avalo TherapeuticsAVTX2.7%
- CytokineticsCYTK2.3%
- Revolution MedicinesRVMD2.3%
- AbivaxABVX2.2%
- First Tracks BiotherapeuticsTRAX2.0%
“Since”: first quarter of the current run, unbroken until today. In the details, prices are the quarter-end prices of the quarters in which it added shares, per the 13F. The manager may have bought at any price within each quarter; the SEC only publishes the value at quarter end.
Portfolio by sector
- ● Health Care 99%
- ● SPAC / vehículos 1%
How its portfolio changed (8 quarters)
Q2 2026: 101
Q2 2026: 43%
Q2 2026: 13.2%
Traded turnover: the weight it bought plus the weight it sold in the quarter, divided by two, excluding price moves. The plain “turnover” in the header does include that effect. With a free account: the full history and sectors over time.
Declared options (9)
Besides stocks, Affinity Asset Advisors declared 3 puts (they gain if the stock falls) and 6 calls (they gain if it rises) with a notional of $168M. The 13F reports the value of the underlying shares, not the premium paid, so these figures look large and are not added to the portfolio. Nor does it say whether the option is bought or written, or its strike or expiry: it may be a hedge.
- PUTModernaMRNAnew this quarter$35.0M
- CALLModernaMRNA$33.3M
- CALLARK Genomic Revolution ETFARKGnew this quarter$31.5M
- CALLEli LillyLLYnew this quarter$24.0M
- PUTOmerosOMERnew this quarter$13.4M
- CALLAlkermesALKSnew this quarter$13.1M
- CALLuniQureQURE$9.2M
- PUTEvommuneEVMNnew this quarter$6.6M
- CALLSummit TherapeuticsSMMTnew this quarter$1.5M
Stakes above 5% (13D/13G)
Companies where this filer reported holding 5% or more of the shares. It is the figure from its latest filing on each one; history since December 2024.
How we classify it
Investment firm, per its Form ADV of Jul 27, 2026 (high confidence).
The data, as reported: AFFINITY ASSET ADVISORS, LLC (CRD 312788): 7.B private funds: 1 hedge, 1 pe (gross assets $2.5 bn); 5.D assets by client type: pooled vehicles 100% (of $2.5 bn)
The type comes from a rule applied to that data. If it looks wrong, tell us.
Not counted as a concentrated manager: its portfolio is not within 5 to 100 positions; its top 10 positions are under 45%. Its portfolio is shown all the same, but it is left out of manager counts, the consensus and the ranking. How this is decided
Similar managers by type and size
Same type of filer and a 13F portfolio value between a third and three times this one. It is not a comparison of what they hold.
- EcoR1 CapitalInvestment firm · $2.0 bn
- Bowie Capital ManagementInvestment firm · $2.0 bn
- Voss CapitalInvestment firm · $2.0 bn
- Casdin CapitalInvestment firm · $2.0 bn
- Abrams Bison InvestmentsInvestment firm · $2.0 bn
- Gobi CapitalInvestment firm · $2.0 bn